deamidation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-05. Anything still debated is marked as such rather than presented as settled.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | RP-HPLC, 214 nm | Wavelength affects relative peak areas |
| Identity confirmation | LC-MS/MS | Precursor and fragment ion masses compared |
| Common degradation | Deamidation, oxidation | Amide and methionine residues are main sites |
| Working solution storage | 2-8 °C, short term | Longer holding favours frozen aliquots |
| Adsorption risk | Higher below 1 mg/mL | Glass and plastic surfaces both affected |
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
== External links == Anatomy figure: 04:04-07 at Human Anatomy Online, SUNY Downstate Medical Center – "Muscles of the anterior chest wall with the pectoralis major muscles removed." "Anatomy photo:18:01-0115". SUNY Downstate Medical Center. Archived from the original on March 5, 2016. – "Thoracic Wall: The Anterior Thoracic Wall" Anatomy figure: 35:06-07 at Human Anatomy Online, SUNY Downstate Medical Center – "Incision and reflection of the external abdominal oblique muscle." Anatomy figure: 35:07-01 at Human Anatomy Online, SUNY Downstate Medical Center – "Incision and reflection of the internal abdominal oblique muscle." "Anatomy photo:35:10-0100". SUNY Downstate Medical Center. Archived from the original on March 5, 2016. – "Anterior Abdominal Wall: The Rectus Abdominis Muscle" Cross section image: pembody/body12a—Plastination Laboratory at the Medical University of Vienna "Anatomy diagram: 25466.180-1". Roche Lexicon - illustrated navigator. Elsevier. Archived from the original on 2012-09-03.
=== Succinate-CoA ligase === Succinate-CoA ligase is a heterodimer composed of an invariant α-subunit and a substrate-specific ß-subunit, encoded by either SUCLA2 or SUCLG2. This combination results in either an ADP-forming succinate-CoA ligase (A-SUCL, EC 6.2.1.5) or a GDP-forming succinate-CoA ligase (G-SUCL, EC 6.2.1.4). The ADP-forming succinate-CoA ligase is potentially the only matrix enzyme generating ATP in the absence of a proton motive force, capable of maintaining matrix ATP levels under energy-limited conditions, such as transient hypoxia.
==== Bangsamoro ==== In the Bangsamoro Parliament, members of the interim body, known as the Bangsamoro Transition Authority, are nominated by both the Moro Islamic Liberation Front (MILF) and the Philippine government, and appointed by the president of the Philippines.
Fernández had in April 2023 announced that he, despite being eligible for a second, would not seek re-election. The Lula government openly supported the candidacy of governing coalition Sergio Massa, defeated in the second round by the libertarian Javier Milei, who during the campaign referred to Lula as "communist" and "corrupt". Lula did not call to congratulate Milei, limiting himself to publishing a protocol message on social media in which the Milei's name was absent. The minister of the Secretariat of Social Communication, Paulo Pimenta, suggested that only after Milei "calls to apologize" would there be dialogue between him and Lula. Days after the victory, Milei sent a letter to Lula, received by Mauro Vieira, in which Milei deviated from his harsh campaign rhetoric and invited Lula to his inauguration. Despite this, Lula did not participate, acting in the same way as Bolsonaro in 2019, who campaigned against Fernández, sending diplomat Mauro Vieira.
Sources: en.wikipedia.org
Alexander von Humboldt Foundation, Member of the Board of Trustees (since 2020) German Future Prize, Member of the Board of Trustees (since 2020) Fritz Thyssen Foundation, Member of the Scientific Advisory Board (since 2020) German National Academic Foundation, Member of the Board of Trustees (since 2020) Center for Infectious Diseases (ZINF), University of Würzburg, Member of the Scientific Advisory Board (2016–2019)
A safety modification to Mark 39 Mod 2 weapons known as Alt 197 had been approved in January 1960, but not yet applied to all deployed weapons prior to the Goldsboro accident, and was not applied to the weapons involved in the accident. Alt 197 replaced the MC-772 Arm/Safe switch with the MC-1288 Arm/Safe switch, with the main change being that the latter would prevent the charging of the low-voltage thermal battery when the Arm/Safe switch was in the "Safe" position, and as such would make sure that no electrical current was available anywhere within the bomb to power additional switches or hardware, legitimately or not. After the accident, all other Mark 39 Mod 2 weapons without the modification were taken off of deployment status ("red-lined") until the modification could be applied to the remaining inventory of the weapons.
In the periodic table, nobelium is located to the right of the actinide mendelevium, to the left of the actinide lawrencium, and below the lanthanide ytterbium. Nobelium metal has not yet been prepared in bulk quantities, and bulk preparation is currently impossible. Nevertheless, a number of predictions and some preliminary experimental results have been done regarding its properties. The lanthanides and actinides, in the metallic state, can exist as either divalent (such as europium and ytterbium) or trivalent (most other lanthanides) metals. The former have fns2 configurations, whereas the latter have fn−1d1s2 configurations. In 1975, Johansson and Rosengren examined the measured and predicted values for the cohesive energies (enthalpies of crystallization) of the metallic lanthanides and actinides, both as divalent and trivalent metals. The conclusion was that the increased binding energy of the [Rn]5f136d17s2 configuration over the [Rn]5f147s2 configuration for nobelium was not enough to compensate for the energy needed to promote one 5f electron to 6d, as is true also for the very late actinides: thus einsteinium, fermium, mendelevium, and nobelium were expected to be divalent metals, although for nobelium this prediction has not yet been confirmed.
Sources: en.wikipedia.org
Filtering removes particulate matter that can block columns or scatter light. A 0.22 micrometre membrane is typical, and the filter material should be checked for peptide adsorption.
Peptides can bind to glass and plastic, so a fraction of the material leaves the solution. The effect is proportionally larger in dilute samples and can bias quantitative results.
Reverse-phase high-performance liquid chromatography is the most widely reported approach. Purity figures should always be quoted together with the wavelength, gradient, and integration parameters used.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.